Urolithin A with immunotherapy for newly diagnosed solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed solid tumor and have not received any previous cancer treatment.
- Your doctor plans to start you on immunotherapy (with or without chemo) as your first treatment.
- You are 18 years or older.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- You must not have taken certain immunosuppressive drugs or mitochondrial supplements (like coenzyme Q10 or NAD+ boosters) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SI-B036 for people with advanced urinary tract cancers or other solid tumors that have spread or cannot be removed. The goal is to see if the drug can shrink or stabilize the cancer.
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.